Sun Pharma’s June quarter results met analyst expectations, signaling future growth. The company is expanding its specialty and innovative medicines portfolio significantly. Strategic initiatives like semaglutide launches and the Organon acquisition are key drivers. Despite US generics pressure, domestic business and specialty products show strong momentum. Analysts maintain a positive outlook, anticipating substantial growth from these ventures.
Warren Buffett sounds alarm as stock market warning returns for only second time in 155 years
Warren Buffett’s caution comes as the S&P 500’s CAPE ratio approaches levels seen only during periods of extreme valuations. While elevated readings can signal weaker
September 19, 2026